Abstract |
A phase II trial of a novel platinum analog, SKI 2053R, was performed in patients with previously untreated extensive-stage disease (ED) small-cell lung cancer (SCLC). SKI 2053R was administered at the dose of 400 mg/m2 every 3 to 4 weeks as a 1-h infusion. After the first cycle, the dose was escalated to 440 mg/m2 based on toxicity. Thirty-eight patients (31 male) were enrolled between June 1995 and August 1997. The median age was 61 years (range, 36-70 years). Six of 37 evaluable patients achieved a partial response (16.2%; 95% confidence interval [CI], 4.4-28.0%). The durations of response were 1.1, 1.5, 1.7, 1.9, 3.4, and 4.6 months. The estimated median survival time was 7.4 months (95% CI, 5.1-9.7 months). Grade 3 or 4 toxicities were not observed. Grade 1 to 2 leukopenia, anemia, and thrombocytopenia were seen in 5 of 68 cycles, 16 of 68, and 2 of 68, respectively. Nonhematologic toxicities included grade 1 to 2 nausea or vomiting (30 of 68 cycles), nephrotoxicity (27 of 68), and hepatotoxicity (13 of 68). SKI 2053R showed a modest antitumor activity with limited toxicities in patients with ED SCLC. Further clinical trials are warranted in SCLC with a higher dose of SKI 2053R.
|
Authors | D Y Zang, K H Lee, J S Lee, J H Lee, W K Kim, S H Kim, W D Kim, D S Kim, J H Kim, B S Kim, Y B Cho, D K Kim, K H Kim |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 22
Issue 5
Pg. 495-8
(Oct 1999)
ISSN: 0277-3732 [Print] United States |
PMID | 10521066
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Malonates
- Organoplatinum Compounds
- SKI 2053R
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(chemistry, therapeutic use)
- Carcinoma, Small Cell
(drug therapy, mortality)
- Female
- Hematologic Diseases
(chemically induced)
- Humans
- Korea
(epidemiology)
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Malonates
(chemistry, therapeutic use)
- Middle Aged
- Nausea
(diagnosis)
- Organoplatinum Compounds
(chemistry, therapeutic use)
- Survival Rate
|